SUBSCRIBE
SUBSCRIBE
News   Policy

Hemispherx Biopharma Responding to FDA’s Ampligen Questions

November 3, 2009 | 
1 min read
Bookmark and Share

Philadelphia Business Journal -- Hemispherx Biopharma said Monday its plans to “complete all outstanding queries” from the Food and Drug Administration regarding the company’s new drug application for Ampligen this month and next.
Regulatory
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst
Illustration showing businessman trying to create his own road
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
 · 
1 min read
 · 
Jef Akst
Creative concept of leadership and innovation with a glowing blue light bulb leading paper planes. Symbol of advanced technology, AI-driven strategy, and visionary direction in a digital future.
Regulatory
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
September 15, 2026
 · 
1 min read
 · 
Heather McKenzie